Golden State Equity Partners Aerovate Therapeutics, Inc. Transaction History

Golden State Equity Partners

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 02, 2024	BUY	$9.58 - $24.25 $3,353 - $8,487	350 Added 3.32%	10,880 $246,000
Q1 2023 Jun 01, 2023	SELL	$19.17 - $27.7 $200,326 - $289,465	-10,450 Reduced 49.81%	10,530 $212 Million
Q1 2022 May 18, 2022	BUY	$8.25 - $18.33 $173,085 - $384,563	20,980 New	20,980 $385,000
Q1 2022 May 16, 2022	SELL	$8.25 - $18.33 $131,422 - $291,996	-15,930 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$9.14 - $21.54 $145,600 - $343,132	15,930 New	15,930 $188,000

28.1M

116K

26.6K

Ticker AVTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,448,100
Market Cap $65.3M
Description
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which ...

Get notified when there are updates to the investment portfolio of Golden State Equity Partners, based on Form 13F filings with the SEC.

Stay updated on Golden State Equity Partners with notifications on news.